Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models

By January 6, 2022May 1st, 2023Publications

Title: Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models

Date: January 6, 2022
Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery
Virtual Presentation